CYSTIC FIBROSIS CANADA BOARD OF DIRECTORS ANNOUNCES APPOINTMENT OF JEFFREY BEACH AND JENNIFER NEBESKY AS CO-INTERIM CEOs
TORONTO (October 16, 2017) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors has announced that Jeffrey Beach, Chief Executive Director, and Jennifer Nebesky, Chief Marketing and Communications Officer, will lead the organization as Co-Interim Chief Executive Officers (CEOs). Their tenure will begin on November 6, 2017 following the departure of current CEO Norma Beauchamp. Jeffrey will oversee the regional activities of both staff and volunteers, and Jennifer will oversee the teams at the national office.
“Both Jennifer and Jeff have an established record of leadership, tenacity, and a thorough understanding of our community and the organization,” said Mitch LePage, Chairman of the CF Canada Board of Directors. “The Board is excited for them to lead CF Canada while we diligently focus on recruiting for a permanent leader who will steer our team towards a world without CF.”
As one of the world’s top three charitable organizations committed to find a cure or control for cystic fibrosis, CF Canada remains as determined as ever to stay the course as a leader in CF care and research. These appointments represent an exciting time for the organization and will ensure the continued focus on the vision of a world without cystic fibrosis.
“I am grateful for the opportunity to step in and ensure work on the existing strategic plan continues seamlessly while the Board of Directors selects a permanent leader. Now more than ever, it’s important for us to remain focused on our commitment to those living, loving, or caring for someone with CF,” said Jennifer Nebesky.
“Our mission is clear: to end CF. Canada has long been a leader in the race to achieve that mission – from discovering the CF gene, to implementing a high-fat diet. I am honoured to co-lead the team that has set the bar so high for CF research, advocacy and care, and remain aligned with our organizational values and standards,” said Jeff Beach.
CF Canada will continue to fund targeted world-class research, support and advocate for high-quality individualized CF care and raise and allocate funds for these purposes. While the process of selecting a permanent leader continues, so will work on the many projects in progress such as the OneCFocus 2020 strategic direction, year-end giving campaign, the CFIT (Cystic Fibrosis Individualized Therapy) Program, the Walk to Make CF History and more. Above all, CF Canada remains focused on the vision of a world without cystic fibrosis and looks forward to the future of the organization.
About cystic fibrosis
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults. It is a multi-system disease that affects mainly the lungs and the digestive system. In the lungs, where the effects are most devastating, a build-up of thick mucus causes severe respiratory problems. Mucus also builds up in the digestive tract, making it difficult to digest and absorb nutrients from food. As improved therapies have helped to address the malnutrition issues, most deaths related to cystic fibrosis are now due to lung disease. There is no cure. In Canada on average, one baby in 3,500 suffers from cystic fibrosis while in Québec, the average is one baby in 2,500.
Cystic Fibrosis Canada
Cystic Fibrosis Canada is one of the three principal charitable organizations committed to finding a cure for cystic fibrosis and is an internationally recognized leader in funding research, innovation and clinical care. Cystic Fibrosis Canada has invested more funding in life-saving CF research and care than any other non-governmental agency in Canada. Since 1960, Cystic Fibrosis Canada has invested more than $244 million in leading research, care and advocacy, resulting in one of the world’s highest survival rates for Canadians living with cystic fibrosis.
For more information and media requests, please contact:
Jennifer Stranges, Coordinator, Corporate Communications
416-485-9149 ext. 290
Back to Listing